Logo Quest Diagnostics

Quest Diagnostics (DGX) stock: analyst price target and their real reliability

Live quote · data updated Oct 14, 2026
Quest Diagnostics · Health Care · ref. ETF XLV · 51 calls · price $230.46
🏆JPI 2026 portfoliosSee tracking →
What the company does: Quest Diagnostics Incorporated provides diagnostic testing and services in the United States.

📈 Quest Diagnostics (DGX) stock price

$230.46+24.3% over range
Oct 14, 25low $173.49 · high $247.45Oct 13, 26
📏 Click 2 points (left → right) to measure the change · click again to clear.
SellBuy
Hold
33% recommend buying · 6 analysts
📊 JPI status : Quest Diagnostics has never appeared in a JPI ranking (Fair or Risk +) — our methods haven't picked it to date. See the selected stocks →

🎯 DGX price target & analyst consensus — price $230

The price target · all analysts combined (6 targets)
Highest target · 3 firms of 6$260+12.8%
Median target · of 6 targets$257.5+11.7%
Lowest target · 1 firm of 6$245+6.3%
Current price$230.46
Where these 6 targets sit · versus the current price · 1 target per firm, last 6 months
Above the price 6100% $245 ↔ $260
⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: JP Morgan — 68% of its targets hit on this sector (364 calls tested). It aims for $250 (+8.5 %), call made on July 29, 2026, maturing on July 29, 2027 (77 d ago).

The 6 reliable analysts $258+12 %
How to read it: the 6 reliable firms are not filtered by optimism — 6 aim above the price, 0 below, hence their $258 median.
The consensus · 6 ratings (last 6 months)
Strong Buy00%
Buy233%
Hold467%
Sell00%
Strong Sell00%
Go deeper on the analysts
All analysts (the consensus)  ·  vs  ·  the best (those who've been right)
💬 A question about Quest Diagnostics? The JPI assistant answers using our backtest data.

💰 Quest Diagnostics dividend: yield, history & growth › open the full page

1.51%annual yield
📈 Steady dividend — 14 yrs of consecutive dividend increases
That's ~$3.26 per share per year.

📈 Quest Diagnostics fundamentals: valuation, margins & growth › open the full page

P/E 24.5Net margin 9.2 %Revenue growth +10.2 %Fairly valued

Revenue, net income and margin per year

Revenue Net income · hover a bar for details
2022
marg. 10 %
2023
Rev −6%Profit −10%
2024
Rev +7%Profit +2%
2025
Rev +12%Profit +14%

🔎 Detailed analyses

✅ Historical analyst reliability on DGX

Hit rate measured on targets already matured (12 months), replayed against real prices. Click a header to sort.

Firm ↕ % right i ↕ Gain vs sector i ↕ Calls i ↕
Baird ↗ 100% +17.3% 4
Citigroup ↗ 100% +14.8% 4
Deutsche Bank ↗ 100% +8.0% 3
UBS ↗ 100% +5.3% 2
Mizuho ↗ 79% +12.8% 14
Jefferies ↗ 67% +16.0% 3
Credit Suisse 67% +6.5% 6
Barclays ↗ 67% +6.3% 3
Morgan Stanley ↗ 58% +5.7% 12
Canaccord Genuity ↗ 57% +4.6% 7
See the other 5 firms
Wells Fargo ↗ 25% -25.3% 4
Goldman Sachs ↗ 33% -5.8% 3
Keybanc ↗ 33% -4.7% 3
Argus Research ↗ 33% -2.2% 3
B of A Securities ↗ 56% +1.1% 9

📊 What $1,000 invested in Quest Diagnostics would be worth › open the full page

In short — $1,000 invested in Quest Diagnostics 10 years ago would be worth $2,979 today, i.e. +12%/yr on average. Best year: 2021 (+45%), worst: 2018 (-15%). Price performance, excluding dividends.

If I'd invested $1,000 in Quest Diagnostics

InvestmentWorth todayGain
1 years ago$1,405+40%
3 years ago$1,355+35%
5 years ago$1,779+78%
→ See Quest Diagnostics's full return history + gain calculator

Return by year (Quest Diagnostics)

YearReturn$1,000 invested at year start
2026 (YTD)+22%$1,221 (+22%)
2025+15%$1,405 (+40%)
2024+9%$1,537 (+54%)
→ See Quest Diagnostics's full return history + gain calculator
⚠️ Past performance, not predictive nor advice. Prices in $, excluding dividends. Yahoo Finance data.

📰 Recent news on Quest Diagnostics

Loading news…

📋 All analyst calls on DGX

Barclays ↗
Oct 7, 26
▲ Overweight · 🎯$260
Price at call : $230.81 — upside +13%
Today : $230.46 — upside +13%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Oct 7, 27
■ Hold neutral · not a buy · 🎯$260
Price at call : $244.88 — gap to target +6%
Today : $230.46 — gap to target +13%
🎯 on DGX : no call matured yet · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Sep 21, 27
UBS ↗
Sep 8, 26
■ Neutral neutral · not a buy · 🎯$245
Price at call : $235.46 — gap to target +4%
Today : $230.46 — gap to target +6%
🎯 on DGX : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Sep 8, 27
JP Morgan ↗
Jul 28, 26
■ Neutral neutral · not a buy · 🎯$250
Price at call : $235.22 — gap to target +6%
Today : $230.46 — gap to target +8%
🎯 on DGX : no call matured yet · 📊 on Health : 53.8% · +5.2% (364 calls)
in progress (365j)
matures : Jul 28, 27
UBS ↗
Jul 25, 26
■ Neutral neutral · not a buy · 🎯$232
Price at call : $231.84 — gap to target +0%
Today : $230.46 — gap to target +1%
🎯 on DGX : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Jul 25, 27
Mizuho ↗
Jul 24, 26
▲ Outperform · 🎯$260
Price at call : $231.84 — upside +12%
Today : $230.46 — upside +13%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.4% · +3.4% (222 calls)
in progress (365j)
matures : Jul 24, 27
■ Hold neutral · not a buy · 🎯$250
Price at call : $231.84 — gap to target +8%
Today : $230.46 — gap to target +8%
🎯 on DGX : no call matured yet · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Jul 24, 27
Barclays ↗
Jul 24, 26
▲ Overweight · 🎯$250
Price at call : $231.84 — upside +8%
Today : $230.46 — upside +8%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Jul 24, 27
See the other 43 calls, newest to oldest
Baird ↗
Jul 24, 26
■ Neutral neutral · not a buy · 🎯$255
Price at call : $227.86 — gap to target +12%
Today : $230.46 — gap to target +11%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.3% · +6.1% (302 calls)
in progress (365j)
matures : Jul 24, 27
Baird ↗
Jul 13, 26
■ Neutral neutral · not a buy · 🎯$236
Price at call : $207.35 — gap to target +14%
Today : $230.46 — gap to target +2%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.3% · +6.1% (302 calls)
in progress (365j)
matures : Jul 13, 27
UBS ↗
Apr 22, 26
■ Neutral neutral · not a buy · 🎯$220
Price at call : $199.53 — gap to target +10%
Today : $230.46 — gap to target -5%
🎯 on DGX : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Apr 22, 27
Baird ↗
Apr 22, 26
■ Neutral neutral · not a buy · 🎯$229
Price at call : $204 — gap to target +12%
Today : $230.46 — gap to target -1%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.3% · +6.1% (302 calls)
in progress (365j)
matures : Apr 22, 27
Barclays ↗
Apr 22, 26
▲ Overweight · 🎯$230
Price at call : $204 — upside +13%
Today : $230.46 — upside -0%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Apr 22, 27
■ Hold neutral · not a buy · 🎯$225
Price at call : $204 — gap to target +10%
Today : $230.46 — gap to target -2%
🎯 on DGX : no call matured yet · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Apr 22, 27
■ In-Line neutral · not a buy · 🎯$210
Price at call : $197.82 — gap to target +6%
Today : $230.46 — gap to target -9%
🎯 on DGX : no call matured yet · 📊 on Health : 44.6% · -0.4% (186 calls)
in progress (365j)
matures : Apr 8, 27
Mizuho ↗
Feb 12, 26
▲ Outperform · 🎯$235
Price at call : $206.86 — upside +14%
Today : $230.46 — upside +2%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.4% · +3.4% (222 calls)
in progress (365j)
matures : Feb 12, 27
■ Hold neutral · not a buy · 🎯$220
Price at call : $206.86 — gap to target +6%
Today : $230.46 — gap to target -5%
🎯 on DGX : no call matured yet · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Feb 11, 27
UBS ↗
Feb 11, 26
■ Neutral neutral · not a buy · 🎯$210
Price at call : $206.86 — gap to target +2%
Today : $230.46 — gap to target -9%
🎯 on DGX : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Feb 11, 27
■ In-Line neutral · not a buy · 🎯$220
Price at call : $209.32 — gap to target +5%
Today : $230.46 — gap to target -5%
🎯 on DGX : no call matured yet · 📊 on Health : 44.6% · -0.4% (186 calls)
in progress (365j)
matures : Feb 11, 27
Barclays ↗
Feb 11, 26
▲ Overweight · 🎯$225
Price at call : $209.32 — upside +7%
Today : $230.46 — upside -2%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Feb 11, 27
Jefferies ↗
Feb 11, 26
▲ Buy · 🎯$220
Price at call : $209.32 — upside +5%
Today : $230.46 — upside -5%
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 51.2% · +4.7% (383 calls)
in progress (365j)
matures : Feb 11, 27
Citigroup ↗
Feb 10, 26
■ Neutral neutral · not a buy · 🎯$215
Price at call : $209.32 — gap to target +3%
Today : $230.46 — gap to target -7%
🎯 on DGX : no call matured yet · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Feb 10, 27
Piper Sandler ↗
Oct 27, 25
■ Neutral neutral · not a buy · 🎯$200
Price at call : $178.28 — gap to target +12%
Today : $230.46 — gap to target -13%
🎯 on DGX : no call matured yet · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : Oct 27, 26
Barclays ↗
Oct 22, 25
■ Equal-Weight neutral · not a buy · 🎯$195
Price at call : $183.23 — gap to target +6%
Today : $230.46 — gap to target -15%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Oct 22, 26
■ Hold neutral · not a buy · 🎯$205
Price at call : $183.23 — gap to target +12%
Today : $230.46 — gap to target -11%
🎯 on DGX : no call matured yet · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Oct 22, 26
▲ Outperform · 🎯$210
Price at call : $181.17 — upside +16%
Today : $230.46 — upside -9%
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 53.7% · -6.2% (41 calls)
in progress (365j)
matures : Oct 21, 26
Jefferies ↗
Oct 21, 25
▲ Buy · 🎯$215
Price at call : $181.17 — upside +19%
Today : $230.46 — upside -7%
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 51.2% · +4.7% (383 calls)
in progress (365j)
matures : Oct 21, 26
UBS ↗
Oct 17, 25
■ Neutral neutral · not a buy · 🎯$190
Price at call : $190.41 — gap to target -0%
Today : $230.46 — gap to target -18%
🎯 on DGX : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Oct 17, 26
Mizuho ↗
Oct 17, 25
▲ Outperform · 🎯$210
Price at call : $189.51 — upside +11%
Today : $230.46 — upside -9%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.4% · +3.4% (222 calls)
in progress (365j)
matures : Oct 17, 26
■ In-Line neutral · not a buy · 🎯$190
Price at call : $180.89 — gap to target +5%
Today : $230.46 — gap to target -18%
🎯 on DGX : no call matured yet · 📊 on Health : 44.6% · -0.4% (186 calls)
in progress (365j)
matures : Oct 8, 26
Barclays ↗
Oct 2, 25
■ Equal-Weight neutral · not a buy · 🎯$190
Price at call : $179.33 — gap to target +6%
Today : $230.46 — gap to target -18%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Oct 2, 26
Baird ↗
Aug 25, 25
■ Neutral neutral · not a buy · 🎯$194
Price at call : $180.36 — gap to target +8%
Today : $230.46 — gap to target -16%
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.3% · +6.1% (302 calls)
in progress (365j)
matures : Aug 25, 26
UBS ↗
Jul 23, 25
■ Neutral neutral · not a buy · 🎯$180
Price at call : $171.9 — gap to target +5%
Today : $230.46 — gap to target -22%
🎯 on DGX : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Jul 23, 26
■ Hold neutral · not a buy · 🎯$192
Price at call : $171.9 — gap to target +12%
Today : $230.46 — gap to target -17%
🎯 on DGX : no call matured yet · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Jul 23, 26
Deutsche Bank ↗
Jul 23, 25
■ Hold neutral · not a buy · 🎯$178
Price at call : $171.9 — gap to target +4%
Today : $230.46 — gap to target -23%
🎯 on DGX : no call matured yet · 📊 on Health : 53.1% · +4.5% (292 calls)
in progress (365j)
matures : Jul 23, 26
Jefferies ↗
Jul 22, 25
▲ Buy · 🎯$200
Price at call : $170.48 — upside +17%
Today : $230.46 — upside -13%
Expected +17% · Actual +34% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 51.2% · +4.7% (383 calls)
+33.7%
stock +34% · XLV +18%
matured Jul 22, 26
UBS ↗
Jul 18, 25
■ Neutral neutral · not a buy · 🎯$175
Price at call : $166.45 — gap to target +5%
Today : $230.46 — gap to target -24%
🎯 on DGX : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Jul 18, 26
JP Morgan ↗
May 6, 25
■ Neutral neutral · not a buy · 🎯$190
Price at call : $176.11 — gap to target +8%
Today : $230.46 — gap to target -18%
🎯 on DGX : no call matured yet · 📊 on Health : 53.8% · +5.2% (364 calls)
in progress (365j)
matures : May 6, 26
Piper Sandler ↗
Apr 28, 25
■ Neutral neutral · not a buy · 🎯$200
Price at call : $178.5 — gap to target +12%
Today : $230.46 — gap to target -13%
🎯 on DGX : no call matured yet · 📊 on Health : 46.6% · -1.4% (324 calls)
in progress (365j)
matures : Apr 28, 26
■ Hold neutral · not a buy · 🎯$190
Price at call : $175.87 — gap to target +8%
Today : $230.46 — gap to target -18%
🎯 on DGX : no call matured yet · 📊 on Health : 49.4% · +2.3% (263 calls)
in progress (365j)
matures : Apr 23, 26
Barclays ↗
Apr 23, 25
■ Equal-Weight neutral · not a buy · 🎯$185
Price at call : $173.57 — gap to target +7%
Today : $230.46 — gap to target -20%
🎯 on DGX : no call matured yet · 📊 on Health : 50.1% · +2.0% (645 calls)
in progress (365j)
matures : Apr 23, 26
■ In-Line neutral · not a buy · 🎯$180
Price at call : $173.57 — gap to target +4%
Today : $230.46 — gap to target -22%
🎯 on DGX : no call matured yet · 📊 on Health : 44.6% · -0.4% (186 calls)
in progress (365j)
matures : Apr 23, 26
Baird ↗
Apr 23, 25
▲ Outperform · 🎯$194
Price at call : $173.57 — upside +12%
Today : $230.46 — upside -16%
Expected +12% · Actual +15% · Reason (≥ +15%) : ✗ No
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.3% · +6.1% (302 calls)
+15.0%
stock +15% · XLV +8%
matured Apr 23, 26
Mizuho ↗
Apr 9, 25
▲ Outperform · 🎯$189
Price at call : $164.06 — upside +15%
Today : $230.46 — upside -18%
Expected +15% · Actual +21% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.4% · +3.4% (222 calls)
+20.6%
stock +21% · XLV +8%
matured Apr 9, 26
▲ Buy · 🎯$195
Price at call : $167.96 — upside +16%
Today : $230.46 — upside -15%
Expected +16% · Actual +18% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (1 call matured) · 📊 unranked overall
+17.9%
stock +18% · XLV +2%
matured Apr 2, 26
Baird ↗
Mar 20, 25
▲ Outperform · 🎯$191
Price at call : $167.11 — upside +14%
Today : $230.46 — upside -17%
Expected +14% · Actual +17% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.3% · +6.1% (302 calls)
+17.1%
stock +17% · XLV -1%
matured Mar 20, 26
Citigroup ↗
Mar 4, 25
■ Neutral neutral · not a buy · 🎯$185
Price at call : $175.01 — gap to target +6%
Today : $230.46 — gap to target -20%
🎯 on DGX : no call matured yet · 📊 on Health : 53.1% · +2.4% (516 calls)
in progress (365j)
matures : Mar 4, 26
JP Morgan ↗
Feb 4, 25
■ Neutral neutral · not a buy · 🎯$180
Price at call : $164.87 — gap to target +9%
Today : $230.46 — gap to target -22%
🎯 on DGX : no call matured yet · 📊 on Health : 53.8% · +5.2% (364 calls)
in progress (365j)
matures : Feb 4, 26
Mizuho ↗
Feb 3, 25
▲ Outperform · 🎯$178
Price at call : $163.36 — upside +9%
Today : $230.46 — upside -23%
Expected +9% · Actual +16% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (2 calls matureds) · 📊 on Health : 51.4% · +3.4% (222 calls)
+15.8%
stock +16% · XLV +6%
matured Feb 3, 26
UBS ↗
Feb 3, 25
■ Neutral neutral · not a buy · 🎯$170
Price at call : $163.36 — gap to target +4%
Today : $230.46 — gap to target -26%
🎯 on DGX : no call matured yet · 📊 on Health : 51.7% · +3.1% (358 calls)
in progress (365j)
matures : Feb 3, 26
▲ Outperform · 🎯$174
Price at call : $152.27 — upside +14%
Today : $230.46 — upside -24%
Expected +14% · Actual +19% · Reason (≥ +15%) : ✓ Yes
🎯 on DGX : 100% (1 call matured) · 📊 on Health : 53.7% · -6.2% (41 calls)
+18.5%
stock +19% · XLV +14%
matured Jan 6, 26

Frequently asked questions

Should I buy Quest Diagnostics stock?

This isn't buy advice. For Quest Diagnostics, the analyst consensus is "Hold", with an average price target of $258 (+12% vs the current price). What matters is their past reliability on this stock: the most reliable one is right 100% of the time (4 calls tracked on Quest Diagnostics). We show the numbers — you decide.

Is it too late to buy Quest Diagnostics? How high can it go?

The most bullish analyst target on Quest Diagnostics is $260 (+13% above today's price); the average is $258. That's the upside they see. Check how reliable those analysts have actually been on Quest Diagnostics on our site before trusting it.

Is Quest Diagnostics still a good buy?

The most useful "opinion" isn't an opinion — it's a track record: 15 analysts have a real record on Quest Diagnostics, the best hitting 100% over 4 calls. Current consensus: "Hold". Make your call on data, not noise.

Should you invest in Quest Diagnostics? The case for and against

The arguments for and against, one by one, from the numbers: why invest in DGX (and why hesitate).

What has Quest Diagnostics's past performance been?

Historical returns and a "how much if I had invested" calculator: DGX performance & returns.

Does Quest Diagnostics pay a dividend?

Yield, consistency and growth history of the dividend: DGX's dividend.

Other Health stocks

Go further

JPI AI Analyst AI assistant · JPI Invest
Answers based on the tool’s data · not financial advice · full version (free)